



INTERIM FINANCIAL STATEMENTS
(Unaudited)

Harvest Healthcare Leaders Income ETF

June 30, 2022



Harvest Healthcare Leaders Income ETF

STATEMENTS OF FINANCIAL POSITION			
(Unaudited)			
As at	June 30,		December 31,
	2022		2021
Assets			
Current assets			
Investments	\$	1,050,087,532	\$ 851,583,352
Cash		17,898,951	11,247,485
Dividends receivable		1,704,995	1,299,085
Subscription receivable		1,209,330	443,335
Unrealized appreciation on foreign currency forward contracts (Note 6)		3,724,820	13,439,135
		1,074,625,628	878,012,392
Liabilities			
Current liabilities			
Payable for investments purchased		1,215,713	444,494
Distributions payable (Note 4)		7,666,396	5,702,815
Payable for option contracts written		6,300,094	6,228,456
		15,182,203	12,375,765
Net assets attributable to holders of redeemable units	\$	1,059,443,425	\$ 865,636,627
Net assets attributable to holders of redeemable units			
Series A	\$	980,380,669	\$ 794,105,390
Series B		13,285,297	9,691,668
Series U (CAD)		65,777,459	61,839,569
Series U (USD)		51,101,196	48,886,967
Number of redeemable units outstanding (Note 4)			
Series A		122,124,053	89,949,053
Series B		1,625,000	1,100,000
Series U		6,125,000	5,350,000
Net assets attributable to holders of redeemable units per unit			
Series A	\$	8.03	\$ 8.83
Series B		8.18	8.81
Series U (CAD)		10.74	11.56
Series U (USD)		8.34	9.14

The accompanying notes are an integral part of these financial statements.

Harvest Healthcare Leaders Income ETF

STATEMENTS OF COMPREHENSIVE INCOME (LOSS)			
(Unaudited)			
For the period ended June 30,	2022		2021
Income			
Net gain (loss) on investments			
Dividends	\$	10,028,217	\$ 7,870,407
Net realized gain (loss) on sale of investments		23,732,053	11,800,708
Net change in unrealized appreciation (depreciation) of investments		(61,066,728)	35,300,854
Net gain (loss) on investments		(27,306,458)	54,971,969
Net gain (loss) on derivatives			
Net realized gain (loss) on options written		3,259,335	1,004,513
Net realized gain (loss) on foreign exchange		(6,477,434)	27,938,888
Net change in unrealized appreciation (depreciation) of options written		(1,711,780)	(71,524)
Net change in unrealized appreciation (depreciation) of foreign exchange		(9,536,491)	(16,029,268)
Net gain (loss) on derivatives		(14,466,370)	12,842,609
Total income (net)	\$	(41,772,828)	\$ 67,814,578
Expenses (Note 5)			
Management fees	\$	4,441,630	\$ 2,616,451
Withholding taxes		2,060,433	864,401
Unitholder reporting costs		230,564	190,792
Audit fees		18,471	17,142
Transfer agency fees		6,724	6,496
Custodian fees and bank charges		85,132	84,998
Independent Review Committee fees		14,627	15,888
Filing fees		32,341	41,151
Legal fees		7,000	6,914
Transaction costs (Note 9)		406,508	179,843
Total expenses	\$	7,303,430	\$ 4,024,076
Expenses absorbed by manager (Note 5)		(177,587)	(151,931)
Total expenses (net)		7,125,843	3,872,145
Increase (decrease) in net assets attributable to holders of redeemable units	\$	(48,898,671)	\$ 63,942,433
Increase (decrease) in net assets attributable to holders of redeemable units - Series A	\$	(46,491,530)	\$ 59,951,283
Increase (decrease) in net assets attributable to holders of redeemable units - Series B		(305,509)	327,471
Increase (decrease) in net assets attributable to holders of redeemable units - Series U		(2,101,632)	3,663,679
Increase (decrease) in net assets attributable to holders of redeemable units per unit - Series A (Note 4)	\$	(0.45)	\$ 0.90
Increase (decrease) in net assets attributable to holders of redeemable units per unit - Series B (Note 4)		(0.22)	0.93
Increase (decrease) in net assets attributable to holders of redeemable units per unit - Series U (Note 4)		(0.37)	0.89

The accompanying notes are an integral part of these financial statements.

Harvest Healthcare Leaders Income ETF

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS ALL SERIES (Unaudited)			
For the period ended June 30,	2022		2021
Net assets attributable to holders of redeemable units beginning of period	\$	865,636,627	\$ 499,175,783
Increase (decrease) in net assets attributable to holders of redeemable units	\$	(48,898,671)	\$ 63,942,433
Redeemable unit transactions			
Proceeds from issue of redeemable units		300,926,350	128,738,251
Redemption of redeemable units		(17,965,311)	(3,614,649)
Net redeemable unit transactions	\$	282,961,039	\$ 125,123,602
Distributions to holders of redeemable units			
Net investment income		(2,533,059)	(1,815,461)
Capital gains		(15,573,671)	(23,096,652)
Return of capital		(22,148,840)	(645,302)
Total distributions to holders of redeemable units	\$	(40,255,570)	\$ (25,557,415)
Net assets attributable to holders of redeemable units end of period	\$	1,059,443,425	\$ 662,684,403

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS SERIES A (Unaudited)			
For the period ended June 30,	2022		2021
Net assets attributable to holders of redeemable units beginning of period	\$	794,105,390	\$ 459,115,282
Increase (decrease) in net assets attributable to holders of redeemable units	\$	(46,491,530)	\$ 59,951,283
Redeemable unit transactions			
Proceeds from issue of redeemable units		283,265,029	117,278,495
Redemption of redeemable units		(13,304,608)	(2,064,273)
Net redeemable unit transactions	\$	269,960,421	\$ 115,214,222
Distributions to holders of redeemable units			
Net investment income		(2,316,582)	(1,523,457)
Capital gains		(12,819,627)	(22,081,881)
Return of capital		(22,057,403)	-
Total distributions to holders of redeemable units	\$	(37,193,612)	\$ (23,605,338)
Net assets attributable to holders of redeemable units end of period	\$	980,380,669	\$ 610,675,449

The accompanying notes are an integral part of these financial statements.

Harvest Healthcare Leaders Income ETF

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS SERIES B (Unaudited)			
For the period ended June 30,	2022		2021
Net assets attributable to holders of redeemable units beginning of period	\$	9,691,668	\$ 1,560,493
Increase (decrease) in net assets attributable to holders of redeemable units	\$	(305,509)	\$ 327,471
Redeemable unit transactions			
Proceeds from issue of redeemable units		5,468,523	3,725,428
Redemption of redeemable units		(1,075,293)	-
Net redeemable unit transactions	\$	4,393,230	\$ 3,725,428
Distributions to holders of redeemable units			
Net investment income		(24,679)	(13,034)
Capital gains		(387,222)	(63,464)
Return of capital		(82,191)	(56,135)
Total distributions to holders of redeemable units	\$	(494,092)	\$ (132,633)
Net assets attributable to holders of redeemable units end of period	\$	13,285,297	\$ 5,480,759

STATEMENTS OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE UNITS SERIES U (Unaudited)			
For the period ended June 30,	2022		2021
Net assets attributable to holders of redeemable units beginning of period	\$	61,839,569	\$ 38,500,008
Increase (decrease) in net assets attributable to holders of redeemable units	\$	(2,101,632)	\$ 3,663,679
Redeemable unit transactions			
Proceeds from issue of redeemable units		12,192,798	7,734,328
Redemption of redeemable units		(3,585,410)	(1,550,376)
Net redeemable unit transactions	\$	8,607,388	\$ 6,183,952
Distributions to holders of redeemable units			
Net investment income		(191,798)	(278,970)
Capital gains		(2,366,822)	(951,307)
Return of capital		(9,246)	(589,167)
Total distributions to holders of redeemable units	\$	(2,567,866)	\$ (1,819,444)
Net assets attributable to holders of redeemable units end of period	\$	65,777,459	\$ 46,528,195

The accompanying notes are an integral part of these financial statements.

Harvest Healthcare Leaders Income ETF

STATEMENTS OF CASH FLOWS		
(Unaudited)		
For the period ended June 30,	2022	2021
Operating activities		
Increase (decrease) in net assets attributable to holders of redeemable units	\$ (48,898,671)	\$ 63,942,433
Add (deduct) items not affecting cash:		
Foreign exchange (gain) loss of cash	150,778	16,092
Realized (gain) loss on sale of investments	(23,732,053)	(11,800,708)
Realized (gain) loss on options written	(3,259,335)	(1,004,513)
Change in unrealized (appreciation) depreciation of investments	61,066,728	(35,300,854)
Change in unrealized (appreciation) depreciation of options written	1,711,780	71,524
Change in unrealized (appreciation) depreciation of foreign exchange	9,536,491	16,029,268
Proceeds from sale of investments*	154,856,881	81,303,777
Purchases of investments*	(108,509,727)	(88,883,796)
Net change in non-cash assets and liabilities	(228,086)	(47,796)
Net cash flow provided by (used in) operating activities	\$ 42,694,786	\$ 24,325,427
Financing activities		
Net proceeds from redeemable units issued*	2,302,829	5,794,259
Net redemption of redeemable units*	96,618	(31,737)
Distributions paid to holders of redeemable units	(38,291,989)	(24,653,182)
Net cash flow provided by (used in) financing activities	\$ (35,892,542)	\$ (18,890,660)
Net increase (decrease) in cash during the period	6,802,244	5,434,767
Foreign exchange gain (loss) on cash	(150,778)	(16,092)
Cash, beginning of the period	11,247,485	7,567,193
Cash, end of the period	\$ 17,898,951	\$ 12,985,868
Supplemental disclosure of cash flow information		
Dividends received, net of withholding taxes**	\$ 7,562,803	\$ 6,945,028

*excludes applicable trades that were not settled in cash (in-kind trades)

**included in operating activities

The accompanying notes are an integral part of these financial statements.

Harvest Healthcare Leaders Income ETF

SCHEDULE OF INVESTMENTS				
(Unaudited)				
As at June 30, 2022				
Number of Shares*	Security	Average Cost (\$)	Fair Value (\$)	% of Net Assets
EQUITIES				
Health Care				
369,596	Abbott Laboratories	51,439,731	51,689,582	4.9
274,470	AbbVie Inc.	39,455,921	54,111,088	5.1
315,182	Agilent Technologies, Inc.	56,009,669	48,185,259	4.5
172,952	Amgen Inc.	49,350,373	54,164,374	5.1
655,633	AstraZeneca PLC ADR	46,505,496	55,758,508	5.3
1,015,088	Boston Scientific Corporation	50,313,624	48,697,775	4.6
563,268	Bristol-Myers Squibb Company	45,681,976	55,827,970	5.3
86,348	Elevance Health, Inc.	39,086,621	53,637,389	5.1
135,626	Eli Lilly and Company	36,367,153	56,603,356	5.3
201,830	HCA Healthcare, Inc.	50,499,847	43,661,244	4.1
233,957	Johnson & Johnson	46,205,757	53,457,039	5.0
424,199	Medtronic PLC	56,496,116	49,006,098	4.6
469,341	Merck & Co., Inc.	46,357,163	55,079,055	5.2
483,932	Novartis AG ADR	54,992,601	52,655,197	5.0
854,305	Pfizer Inc.	47,432,184	57,655,247	5.4
64,161	Regeneron Pharmaceuticals, Inc.	48,329,127	48,820,268	4.6
176,846	Stryker Corporation	50,530,734	45,283,663	4.3
80,670	Thermo Fisher Scientific Inc.	52,962,007	56,413,339	5.3
84,129	UnitedHealth Group Incorporated	40,173,466	55,621,429	5.3
242,974	Zoetis Inc., Class A	52,132,496	53,759,652	5.1
Total equities		960,322,062	1,050,087,532	99.1
OPTIONS				
Health Care				
(36,700)	Abbott Laboratories - Jul 2022 @ USD \$105	(118,375)	(238,563)	-
(36,700)	Abbott Laboratories - Jul 2022 @ USD \$110	(86,360)	(75,112)	-
(40,800)	AbbVie Inc. - Jul 2022 @ USD \$144	(161,723)	(430,646)	(0.1)
(19,100)	AbbVie Inc. - Jul 2022 @ USD \$155	(61,996)	(45,483)	-
(31,300)	Agilent Technologies, Inc. - Jul 2022 @ USD \$115	(142,090)	(217,562)	-
(25,700)	Amgen Inc. - Jul 2022 @ USD \$237.5	(199,463)	(275,234)	-
(12,900)	Amgen Inc. - Jul 2022 @ USD \$247.5	(56,964)	(39,354)	-
(97,600)	AstraZeneca PLC - Jul 2022 @ USD \$63	(209,044)	(455,411)	(0.1)
(65,200)	AstraZeneca PLC - Jul 2022 @ USD \$67	(128,432)	(78,051)	-
(100,800)	Boston Scientific Corporation - Jul 2022 @ USD \$38	(93,435)	(90,825)	-
(85,000)	Bristol-Myers Squibb Company - Jul 2022 @ USD \$77	(123,988)	(154,271)	-
(39,700)	Bristol-Myers Squibb Company - Jul 2022 @ USD \$80	(53,181)	(17,375)	-
(8,500)	Elevance Health, Inc. - Jul 2022 @ USD \$460	(160,917)	(291,583)	-
(6,400)	Elevance Health, Inc. - Jul 2022 @ USD \$485	(96,913)	(79,086)	-
(15,000)	Eli Lilly and Company - Jul 2022 @ USD \$300	(181,064)	(502,008)	(0.1)
(15,000)	Eli Lilly and Company - Jul 2022 @ USD \$330	(160,362)	(105,615)	-
(20,000)	HCA Healthcare, Inc. - Jul 2022 @ USD \$175	(131,774)	(60,498)	-
(15,000)	HCA Healthcare, Inc. - Jul 2022 @ USD \$185	(73,573)	(19,887)	-
(34,800)	Johnson & Johnson - Jul 2022 @ USD \$175	(112,395)	(202,919)	-
(13,900)	Johnson & Johnson - Jul 2022 @ USD \$182.5	(55,502)	(16,282)	-
(42,100)	Medtronic PLC - Jul 2022 @ USD \$89	(90,830)	(128,162)	-

Harvest Healthcare Leaders Income ETF

SCHEDULE OF INVESTMENTS (continued) (Unaudited)				
As at June 30, 2022				
Number of Shares*	Security	Average Cost (\$)	Fair Value (\$)	% of Net Assets
OPTIONS (continued)				
Health Care (continued)				
(75,600)	Merck & Co., Inc. - Jul 2022 @ USD \$89	(166,562)	(379,518)	(0.1)
(30,300)	Merck & Co., Inc. - Jul 2022 @ USD \$95	(74,543)	(16,771)	-
(48,000)	Novartis AG - Jul 2022 @ USD \$82.5	(85,693)	(168,366)	-
(57,700)	Novartis AG - Jul 2022 @ USD \$87.5	(52,024)	(25,995)	-
(85,300)	Pfizer Inc. - Jul 2022 @ USD \$48	(169,707)	(538,011)	(0.1)
(85,400)	Pfizer Inc. - Jul 2022 @ USD \$52	(138,599)	(169,287)	-
(6,300)	Regeneron Pharmaceuticals, Inc. - Jul 2022 @ USD \$590	(177,210)	(144,347)	-
(3,100)	Regeneron Pharmaceuticals, Inc. - Jul 2022 @ USD \$610	(56,700)	(33,120)	-
(17,500)	Stryker Corporation - Jul 2022 @ USD \$200	(89,587)	(87,851)	-
(8,100)	Thermo Fisher Scientific Inc. - Jul 2022 @ USD \$520	(136,593)	(306,012)	-
(8,300)	UnitedHealth Group Incorporated - Jul 2022 @ USD \$475	(179,402)	(458,867)	(0.1)
(6,200)	UnitedHealth Group Incorporated - Jul 2022 @ USD \$510	(103,972)	(129,446)	-
(24,100)	Zoetis Inc. - Jul 2022 @ USD \$165	(96,555)	(277,643)	-
(12,000)	Zoetis Inc. - Jul 2022 @ USD \$175	(57,047)	(40,933)	-
Total options		(4,082,575)	(6,300,094)	(0.6)
Total investments		956,239,487	1,043,787,438	98.5
Foreign currency forward contracts (Note 6)			3,724,820	0.4
Other assets less liabilities			11,931,167	1.1
Net assets attributable to holders of redeemable units			1,059,443,425	100.0

* For options, this represents the total number of shares of the equity position available for assignment under the terms of the option contracts.

Harvest Healthcare Leaders Income ETF

NOTES TO THE INTERIM FINANCIAL STATEMENTS (Unaudited)

June 30, 2022

1. GENERAL INFORMATION

Harvest Healthcare Leaders Income ETF (the "Fund") is an investment fund established under the laws of the Province of Ontario pursuant to a Declaration of Trust dated November 19, 2014 and as amended and restated, being the inception date. There was no significant activity in the Fund from the date of inception to commencement of operations on December 18, 2014. On December 18, 2014, the Fund completed an initial public offering of 9,500,000 units at \$10.00 per unit for gross proceeds of \$95,000,000. On January 13, 2015, an overallotment option was exercised for an additional 259,149 units at a price of \$10.00 per unit for gross proceeds of \$2,591,490. On March 13, 2015, the Fund completed a secondary offering of 3,000,000 units at \$10.10 per unit for gross proceeds of \$30,300,000. Related to this offering an overallotment option was exercised for an additional 450,000 units at a price of \$10.10 per unit for gross proceeds of \$4,545,000. On May 7, 2015, the Fund completed a secondary offering of 2,360,000 units at \$10.20 per unit for gross proceeds of \$24,072,000. Related to this offering an overallotment option was exercised for an additional 145,000 units at a price of \$10.20 per unit for gross proceeds of \$1,479,000. The address of the Fund's registered office is 610 Chartwell Rd, Oakville, Ontario, L6J 4A5.

The Fund's investment objectives are to provide unitholders with the opportunity for capital appreciation, monthly cash distributions and lower overall volatility of Portfolio returns than would otherwise be experienced by owning Equity Securities¹ of the Healthcare Leaders¹ directly. As part of the investment strategy, the Fund will invest in an equally-weighted portfolio of Equity Securities of 20 Healthcare Issuers¹ from the Healthcare Leaders Investable Universe¹ that have a market capitalization of at least US\$5 billion at the time of investment and have options in respect of their Equity Securities listed on a recognized options exchange.

On September 19, 2016, unitholders approved the conversion of the units of the Fund into an Exchange Traded Fund ("ETF") effective October 24, 2016 and the name of the Fund changed to Healthcare Leaders Income ETF. The units began trading as an ETF under the symbol HHL. Prior to the conversion, units traded under the symbol HHL.UN as a closed end fund. On February 3, 2017, the Fund launched a USD series U unit of the Fund. The series U unit began trading under the symbol HHL.U.

On June 14, 2018, the Fund changed its name from Healthcare Leaders Income ETF to Harvest Healthcare Leaders Income ETF. No changes were made to the investment objective, strategies or management of the Fund.

On March 10, 2020, the Fund began offering Series B Units. The initial price was \$8.00 per unit and 125,000 units were issued. The Series B Units began trading under the symbol HHL.B. The Series B Units are unhedged and designed for investors who want to maintain exposure to currency fluctuations of the foreign denominated holdings in the Fund compared to the Canadian dollar.

2. BASIS OF ACCOUNTING

These interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to the preparation of interim financial statements, including International Accounting Standard 34, Interim Financial Reporting. These interim financial statements were authorized for issue by Harvest Portfolios Group Inc. (the "Manager") on August 17, 2022.

3. SIGNIFICANT ACCOUNTING POLICIES

Financial instruments

The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments not measured at fair value through profit or loss ("FVTPL"). Transaction costs on financial assets and liabilities at FVTPL are expensed as incurred. Regular way purchases and sales of financial assets are recognized at their trade date. The Fund's investments and derivative assets and liabilities are measured at FVTPL based on its business model. The Fund's obligation for net assets attributable to holders of redeemable units is presented at the redemption amount. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid. Carrying values of other financial assets and liabilities at amortized cost approximate their fair values due to the short term to maturity. The Fund's accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its net asset value ("NAV") for transactions with unitholders. As at June 30, 2022 and December 31, 2021, there were no differences between the Fund's NAV per security and its net assets per security calculated in accordance with IFRS 9.

¹ As defined in the Fund's prospectus dated June 6, 2022.

Harvest Healthcare Leaders Income ETF

Fair value of investments and derivatives

Investments and derivatives that are traded in an active market are valued at their closing prices through recognized public stock exchanges or through recognized investment dealers on the valuation date. The Fund uses the last traded market price that falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on specific facts and circumstances. Investments held are represented by equities. Derivatives held include options and foreign currency forward contracts.

Investments and derivatives held that are not traded in an active market are valued using valuation techniques, on such basis and in such a manner established by the Manager. The value of any security for which, in the opinion of the Manager, the published market quotations are not readily available shall be the fair value as determined by the Manager. The fair values of certain securities may be determined using valuation models that are based, in part, on assumptions that are not supported by observable market inputs. These methods and procedures may include, but are not limited to, performing comparisons with prices of comparable or similar securities, obtaining valuation related information from issuers and/or other analytical data relating to the investment and using other available indication of value. These values are independently assessed internally to ensure that they are reasonable. However, because of the inherent uncertainty of valuation, the estimated fair values for the aforementioned securities and interests may be materially different from the values that would be used had a ready market for the security existed. The fair values of such securities are affected by the perceived credit risks of the issuer, predictability of cash flows and length of time to maturity.

Classification of redeemable units

Under IFRS, IAS 32 Financial Instruments – Presentation requires that units or shares of an entity which include a contractual obligation for the issuer to repurchase or redeem them for cash or another financial asset be classified as a financial liability unless certain criteria are met. The Fund's units include different redemption rights and in some instances are at 95% of market value of the units on the exchange. As a result, the Fund's units contain multiple contractual obligations and are presented as financial liabilities as they do not meet the criteria for classification as equity.

Cash

Cash is comprised of cash on deposit.

Investment transactions and income recognition

Net realized gain (loss) on sale of investments and net change in unrealized appreciation (depreciation) of investments are determined on an average cost basis. Dividend income is accounted for on the ex-dividend date. The cost of investments is determined using the average cost method.

Allocation of income and expense, and realized and unrealized capital gains and losses

Management fees directly attributable to a series are charged to that series. The Fund's shared operating expenses, income, and realized and unrealized capital gains and losses are generally allocated proportionately to each series based upon the relative net assets attributable to holders of redeemable units of each series. Realized and unrealized gains and losses from foreign currency forward contracts are allocated to Series A only.

Foreign currency translation

The Fund's subscriptions and redemptions are predominately denominated in Canadian dollars which is also the Fund's functional and presentation currency. Purchases and sales of investments denominated in foreign currencies and foreign currency dividend and interest income are translated into Canadian dollars at the rate of exchange prevailing at the time of the transactions. Realized and unrealized foreign currency gains or (losses) on investments are included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on sale of investments" and "Net change in unrealized appreciation (depreciation) of investments", respectively. Realized and unrealized foreign currency gains or (losses) on options are included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on options written" and "Net change in unrealized appreciation (depreciation) of options written", respectively. Realized and unrealized foreign currency gains or losses on assets and liabilities, other than investments and options, denominated in foreign currencies are included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on foreign exchange" and "Net change in unrealized appreciation (depreciation) of foreign exchange", respectively. Foreign currency assets and liabilities in the Statements of Financial Position are translated into Canadian dollars on the statement date.

Foreign currency forward contracts

The Fund will enter into foreign currency forward contracts to hedge against exposure to foreign currency fluctuations. The fair value of these contracts is based on the difference between the contract rate and current forward market rate for the underlying currency at the measurement date applied to the contract's notional amount and adjusted for counterparty risk. Upon closing of a contract, the gain or loss is included in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on foreign exchange". The unrealized gains or losses on forward contracts are included in the Statements of Comprehensive Income (Loss) in "Net change in unrealized appreciation (depreciation) of foreign exchange" and are allocated to Series A only until closed out or partially settled.

Harvest Healthcare Leaders Income ETF

Offsetting financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the Statements of Financial Position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

Redeemable units valuation

The NAV of each series on a particular date will be equal to each series' proportionate share of the assets of the Fund less each series' proportionate share of the liabilities of the Fund except for forwards which are only attributed to Series A, expressed in Canadian dollars at the applicable exchange rate on such date. The NAV and NAV per unit will be calculated on any day on which the Toronto Stock Exchange ("TSX") is open for trading ("Business Day").

Options

An option is a contractual arrangement under which the seller (writer) grants the purchaser (holder) the right, but not the obligation, either to buy (a call option) or sell (a put option) at or by a set date or during a set period, a specific amount of securities or a financial instrument at a pre-determined price. The seller receives a premium from the purchaser in consideration for the assumption of a future securities price.

The premium received upon writing an option is recorded at cost as "Payable for option contracts written" in the Statements of Financial Position. As long as the position of the written option is maintained, the liability for written options is revalued at an amount equal to the current market value of the option. Any gain or loss resulting from revaluation is reflected in the Statements of Comprehensive Income (Loss) in "Net changes in unrealized appreciation (depreciation) of options written".

The gain or loss on sale or expiry of options is reflected in the Statements of Comprehensive Income (Loss) in "Net realized gain (loss) on options written".

Increase (decrease) in net assets attributable to holders of redeemable units per unit

"Increase (decrease) in net assets attributable to holders of redeemable units per unit" in the Statements of Comprehensive Income (Loss) represents the increase (decrease) in net assets attributable to holders of redeemable units per series, divided by the weighted average units outstanding for the financial period for the respective series.

Critical accounting estimates and judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

- a) Fair value measurement of derivatives and securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. Refer to Note 7 for further information about the fair value measurement of the Fund's financial instruments.

- b) Classification and measurement of investments and derivatives under IFRS 9

In classifying and measuring financial instruments held by the Fund, the Manager is required to make significant judgments about the business model in which the portfolio of investments and derivatives is held. The Manager has determined that the Fund's business model is one in which its portfolio is managed, and performance evaluated on a fair value basis under IFRS 9.

4. REDEEMABLE UNITS

The authorized capital of the Fund consists of an unlimited number of transferable units of each series, each of which represents an equal, undivided interest in their respective series' net assets of the Fund. Except as provided in the Declaration of Trust, all units have equal rights and privileges. Each unit is entitled to one vote at all meetings of unitholders and is entitled to participate equally in any and all distributions made by the Fund. The Series A units, Series B units and Series U units trade on the TSX under the symbol HHL, HHL.B and HHL.U, respectively. As at June 30, 2022, the closing price for Series A, Series B and Series U units was \$8.03, \$8.16 and \$8.33 USD per unit, respectively (December 31, 2021 – Series A \$8.84; Series B \$8.84; Series U \$9.21 USD).

Subscriptions and Redemptions

On any Business Day, a designated broker or underwriter may place a subscription or redemption order for an integral multiple of the prescribed number of units of the ETF.

Harvest Healthcare Leaders Income ETF

If the subscription or redemption order is accepted, the ETF will issue or redeem units to/from the designated broker or underwriter generally by the second trading day after the date on which the subscription or redemption order is accepted. For each prescribed number of units issued or redeemed, a designated broker or underwriter must deliver or receive payment consisting of:

- (a) A basket of applicable securities and cash in an amount sufficient so that the value of the securities, and the cash received is equal to the NAV of the units issued or redeemed; or
- (b) Cash in the amount equal to the NAV of the units issued or redeemed.

On any Business Day, unitholders may redeem units for cash or exchange units for baskets of securities and cash. Units redeemed for cash may be redeemed at a redemption price per unit equal to 95% of the closing price for the units on the TSX on the effective day of the redemption, subject to a maximum redemption price per unit equal to NAV. Units exchanged for baskets of securities will be exchanged at a price equal to the NAV of the units on the effective date of the exchange request, payable by delivery of baskets of securities and cash. The units will be redeemed in the exchange.

The following units were issued and/or redeemed during the period:

	Series A	Series B	Series U
Total outstanding as at January 1, 2021	59,124,053	200,000	3,775,000
Redeemable units issued	14,775,000	475,000	750,000
Redeemable units redeemed	(250,000)	-	(150,000)
Total outstanding as at June 30, 2021	73,649,053	675,000	4,375,000
Total outstanding as at January 1, 2022	89,949,053	1,100,000	5,350,000
Redeemable units issued	33,775,000	650,000	1,100,000
Redeemable units redeemed	(1,600,000)	(125,000)	(325,000)
Total outstanding as at June 30, 2022	122,124,053	1,625,000	6,125,000

The weighted average number of units outstanding during the period ended June 30, 2022 was 103,756,373 units (2021 – 66,505,407 units) for Series A, 1,368,094 units for Series B (2021 – 350,552) and 5,712,983 (2021 – 4,123,481) for Series U.

Distributions

The Fund is required to pay distributions in an amount not less than the amount necessary to ensure the Fund will not be liable for income taxes on realized capital gains, dividends and interest. The Fund intends to make monthly cash distributions to unitholders of record on the last Business Day of each month and pay such cash distributions on or before the 15th day of the following month. The total distribution amount was \$40,255,570 (Series A \$37,193,612, Series B \$494,092 and Series U \$2,567,866) for the period ended June 30, 2022 (2021 – Series A \$23,605,338, Series B \$132,633 and Series U \$1,819,444).

The Fund made available to unitholders the opportunity to reinvest monthly distributions from the Fund in additional Series A, Series B and/or Series U units, as applicable, by participating in a distribution reinvestment plan which would provide that cash distributions made by the Fund, at the election of a unitholder, be automatically reinvested in additional Series A, Series B or Series U units, as applicable, on such unitholder's behalf in accordance with the terms of the plan. Reinvestment of distributions occur through market purchases only.

5. RELATED PARTY TRANSACTIONS AND OTHER EXPENSES

The Fund pays management fees and other expense reimbursements to Harvest, as noted below in Management Fees, Operating Expenses and Other Expenses sections.

In addition, other ETFs that are managed by Harvest invest in units of the Fund. The Fund does not receive or pay any commission to Harvest or the related ETFs on these transactions. The related ETFs purchased (sold) a total of \$33,248,031 of Class A units of the Fund during the period ending June 30, 2022.

As at June 30, 2022, the related ETFs owned 3,916,740 Class A units or 3.0% of the Fund.

Management fees

The Manager is responsible for managing the Fund's overall business and operations and provides key management personnel to the Fund. The Manager is entitled to a fee of 0.85% of the average daily NAV, plus applicable taxes, per annum of the Fund.

Harvest Healthcare Leaders Income ETF

Operating expenses

The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of units, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee ("IRC"), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

Other expenses

The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to unitholders and other unitholder communications; a reasonable allocation of salaries and benefits; and other administrative expenses and costs incurred in connection with the Fund's continuous public offering and other obligations. These expenses are allocated by the Manager on a reasonable basis, across all the Harvest Portfolios Group Inc. funds, and series of each applicable fund. These expenses were \$172,383 for the period ended June 30, 2022 (2021 - \$159,492) and are included in the unitholder reporting costs on the Statements of Comprehensive Income (Loss).

Waivers and absorptions

At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. There were no management fee waivers for the period ended June 30, 2022 or 2021. The Manager absorbed \$177,587 of expenses of the Fund for the period ended June 30, 2022 (2021 – \$151,931). The Manager may cease doing so at any time without notice to unitholders.

6. FOREIGN CURRENCY FORWARD CONTRACTS

The Fund enters into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies of Series A only. Foreign currency forward contracts entered into by the Fund represent a firm commitment to buy or sell a currency at a specified value and point in time based upon an agreed or contracted quantity. The value of each foreign currency forward contract is the difference between the contract rate and the current forward rate at the measurement date applied to the contract's notional amount and adjusted for counterparty risk.

At June 30, 2022 and December 31, 2021, the Fund had entered into the following foreign currency forward contracts:

As at June 30, 2022					
Counterparty	Settlement date	Purchased currency	Sold currency	Unrealized gain (loss)	Contract price
National Bank of Canada – credit rate A	July 13, 2022	CAD \$102,016,449	USD \$79,233,000	\$31,574	0.7767
Royal Bank of Canada – credit rating AA-	July 13, 2022	CAD \$102,064,385	USD \$79,233,000	\$79,510	0.7763
Bank of Montreal – credit rating A+	August 17, 2022	CAD \$234,959,231	USD \$181,611,000	\$1,197,137	0.7729
Canadian Imperial Bank of Commerce – credit rating A+	August 17, 2022	CAD \$84,338,455	USD \$65,500,000	\$29,590	0.7766
Canadian Imperial Bank of Commerce – credit rating A+	August 17, 2022	CAD \$234,919,277	USD \$181,611,000	\$1,157,182	0.7731
Toronto Dominion Bank – credit rating AA-	August 17, 2022	CAD \$234,991,921	USD \$181,611,000	\$1,229,827	0.7728
Total				\$3,724,820	

Harvest Healthcare Leaders Income ETF

As at December 31, 2021					
Counterparty	Settlement date	Purchased currency	Sold currency	Unrealized gain (loss)	Contract price
National Bank of Canada – credit rate A	January 19, 2022	CAD \$99,221,169	USD \$78,297,000	\$178,074	0.7891
Royal Bank of Canada – credit rating AA-	January 19, 2022	CAD \$99,271,044	USD \$78,297,000	\$227,949	0.7887
Bank of Montreal – credit rating A+	February 11, 2022	CAD \$188,587,743	USD \$145,802,000	\$4,146,791	0.7731
Canadian Imperial Bank of Commerce – credit rating A+	February 11, 2022	CAD \$188,782,972	USD \$145,802,000	\$4,342,020	0.7723
Canadian Imperial Bank of Commerce – credit rating A+	February 11, 2022	CAD \$32,653,183	USD \$25,510,000	\$382,784	0.7812
Toronto Dominion Bank – credit rating AA-	February 11, 2022	CAD \$188,602,469	USD \$145,802,000	\$4,161,517	0.7731
Total				\$13,439,135	

Offsetting of foreign currency forward contracts

As at June 30, 2022 and December 31, 2021, the Fund did not have any foreign exchange settlements for its foreign currency forward contracts that met the criteria for offsetting in the Statements of Financial Position. The following tables present the recognized financial instruments that were not offset as at June 30, 2022 and December 31, 2021. There would be no further offsetting in the event of bankruptcy of the counterparty.

June 30, 2022			
Financial assets and liabilities	Gross assets (liabilities)	Amounts eligible for offset	Net offset amounts
Derivative assets	\$3,724,820	-	\$3,724,820
Derivative liabilities	-	-	-

December 31, 2021			
Financial assets and liabilities	Gross assets (liabilities)	Amounts eligible for offset	Net offset amounts
Derivative assets	\$13,439,135	-	\$13,439,135
Derivative liabilities	-	-	-

7. FINANCIAL RISK MANAGEMENT

Investment activities of the Fund expose it to a variety of financial risks: credit risk, liquidity risk and market risk (including interest rate risk, other price risk and currency risk). The Manager seeks to minimize these risks by employing experienced portfolio managers that will manage the security portfolios of the Fund on a daily basis according to market events and the investment objectives of the Fund. To assist in managing risk, the Manager also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy and securities regulations.

Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The value of securities in the Fund's portfolio may be affected by the stock market conditions rather than each company's performance. Developments in the market are affected by general economic and financial conditions. Political, social and environmental factors can also affect the value of any investment. The spread of the coronavirus has caused volatility in the global financial markets and impacted the global economy. Locally and globally restrictions have eased and appear to be less likely in the future however the lasting effects of the previous restrictions have impacted the economy with rising inflation and resulting rising interest rates. In addition to this, the war in Ukraine has further contributed to rising inflation and has added to the economic and financial markets instability. Both events have significantly impacted global

Harvest Healthcare Leaders Income ETF

economies and financial markets and there is uncertainty as to how long this will last or the impact on the financial performance of the Fund's investments and the Fund's future investments.

As at June 30, 2022, 99.1% (December 31, 2021 – 98.4%) of the Fund's net assets attributable to holders of redeemable units were traded on public stock exchanges. If equity prices on these exchanges had increased or decreased by 5%, as at period end, with all other factors remaining constant, net assets attributable to holders of redeemable units would have increased or decreased by approximately \$52,504,377 (December 31, 2021 - \$42,579,168).

In practice, the actual trading results may differ, and the difference could be material.

Currency risk

Currency risk is the risk that the value of investments denominated in currencies other than the functional currency of the Fund will fluctuate as a result of changes in foreign exchange rates. When a Fund buys an investment priced in a foreign currency and the exchange rate between the Canadian dollar and the foreign currency changes unfavorably, it could reduce the value of the Fund's investment.

The table below summarizes the Fund's net exposure to currency risk. Amounts shown are based on the carrying value of monetary and non-monetary assets (including derivatives and the underlying principal (notional) amount of forward currency contracts, if any).

As at June 30, 2022				
Currency	Currency exposure*	Forward contracts*	Net currency exposure*	As a % of net assets
U.S. Dollar	\$1,060,944,501	\$989,564,898	\$71,379,603	6.7

*In Canadian dollars

As at December 31, 2021				
Currency	Currency exposure*	Forward contracts*	Net currency exposure*	As a % of net assets
U.S. Dollar	\$852,881,986	\$ 783,679,443	\$69,202,543	8.0

*In Canadian dollars

The non-monetary currency exposure was \$1,043,787,439 (December 31, 2021 - \$845,354,897) and the monetary exposure was \$17,157,062 (December 31, 2021 - \$7,527,089).

As at June 30, 2022, if the Canadian dollar had strengthened or weakened by 5% in relation to U.S. dollar, with all other variables held constant, the Fund's net assets attributable to holders of redeemable units would have decreased or increased, respectively, by approximately \$3,568,980 or 0.3% (December 31, 2021 - \$3,460,127 or 0.4%). In practice, the actual results may differ from this sensitivity analysis and the difference could be material.

As all of the securities in the portfolio investments are denominated in U.S. dollars and related dividends and premiums from call options received, if applicable, are in U.S. dollars, the Fund enters into a foreign currency forward contract on substantially all of the value of the proportionate share of Series A portfolio investments back to the Canadian dollar at all times.

Interest rate risk

Interest rate risk arises from the possibility that changes in interest rates will affect future cash flows or fair value of financial instruments. Interest rate risk arises when the Fund invests in interest-bearing financial instruments. As at June 30, 2022 and December 31, 2021, the Fund did not hold any bonds or money market instruments; therefore, the Fund had no significant exposure to interest rate risk.

Liquidity risk

Liquidity risk is defined as the risk that a fund may not be able to settle or meet its obligations on time or at a reasonable price. The Fund is exposed to redemption of units as described in Note 4. Since the settlement of redemptions is primarily by delivery of securities, the Fund is not exposed to any significant liquidity risk. Therefore, in order to maintain sufficient liquidity, the Fund primarily invests in securities that are actively traded in public markets and can be readily disposed of to raise liquidity. In addition, the Fund retains sufficient cash and cash equivalent positions to maintain liquidity.

As at June 30, 2022 and December 31, 2021, all the Fund's financial liabilities had maturities of less than three months.

Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund.

Harvest Healthcare Leaders Income ETF

All transactions executed by the Fund in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

The Fund enters into foreign currency forward contracts which are exposed to credit risk. The maximum credit risk exposure is the unrealized gain on the forward contracts.

As at June 30, 2022 and December 31, 2021, the Fund did not have significant credit risk exposure. All cash held by the fund is held with a reputable and regulated financial institution.

Fair value of financial instruments

The Fund classifies fair value measurements within a hierarchy which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3: Inputs for the asset or liability that are not based on observable market data.

The table below summarizes the fair value of the Fund's financial instruments using the following fair value hierarchy:

Transfers between levels of the fair value hierarchy are deemed to have occurred at the beginning of the reporting period.

Securities classification:

Investments at fair value as at June 30, 2022				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Totals (\$)
Financial Assets				
Equities				
Common Stock	941,673,827	-	-	941,673,827
ADR	108,413,705	-	-	108,413,705
Derivatives				
Foreign currency forward contracts	-	3,724,820	-	3,724,820
Total Financial Assets	1,050,087,532	3,724,820	-	1,053,812,352
Financial Liabilities				
Derivatives				
Options	(6,300,094)	-	-	(6,300,094)
Total Financial Liabilities	(6,300,094)	-	-	(6,300,094)

Harvest Healthcare Leaders Income ETF

Investments at fair value as at December 31, 2021				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Totals (\$)
Financial Assets				
Equities				
Common Stock	770,091,230	-	-	770,091,230
ADR	81,492,122	-	-	81,492,122
Derivatives				
Foreign currency forward contracts	-	13,439,135	-	13,439,135
Total Financial Assets	851,583,352	13,439,135	-	865,022,487
Financial Liabilities				
Derivatives				
Options	(6,228,456)	-	-	(6,228,456)
Total Financial Liabilities	(6,228,456)	-	-	(6,228,456)

There were no Level 3 securities held by the Fund as at June 30, 2022 and December 31, 2021, and there were no transfers between Level 1 and Level 2 for the period ended June 30, 2022 and 2021.

The value of the equities and options is based on quoted prices. The value of the foreign currency forward contract is determined as the difference between the contract rate and the current forward rate at the measurement date applied to the contract's notional amount and adjusted for counterparty risk.

Concentration Risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, product type, industry, sector or counterparty type. The following is a summary of the Fund's concentration risk by country and industry in which the companies held in the portfolio operate.

Geography:

As at	June 30, 2022	December 31, 2021
	% of net assets	% of net assets
United States	88.8	89.0
United Kingdom	5.3	4.4
Switzerland	5.0	5.0
Cash and other assets and liabilities	1.1	0.7
Foreign currency forward contracts	0.4	1.6
Options	(0.6)	(0.7)
Totals	100.0	100.0

Market Segment:

As at	June 30, 2022	December 31, 2021
	% of net assets	% of net assets
Health Care	99.1	98.4
Cash and other assets and liabilities	1.1	0.7
Foreign currency forward contracts	0.4	1.6
Options	(0.6)	(0.7)
Total	100.0	100.0

8. TAXATION

The Fund qualifies as a mutual fund trust under the Income Tax Act (Canada). For tax purposes, the Fund has a December 15 year end. All the Fund's net income for tax purposes and sufficient net capital gains realized in any period are required to

Harvest Healthcare Leaders Income ETF

be distributed to unitholders such that no income tax is payable by the Fund. As a result, the Fund does not record income taxes. Since the Fund does not record income taxes, the tax benefit of capital and non-capital losses has not been reflected in the Statements of Financial Position as a deferred income tax asset. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Non-capital losses may be carried forward for 20 years and applied against future taxable income.

As at the last taxation year end, the Fund had no capital or non-capital losses available to be carried forward for income tax purposes.

The Fund may incur withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown as a separate expense in the Statements of Comprehensive Income (Loss).

As the Manager is a resident of Ontario, the expenses paid by the Fund generally include HST of 13%. HST is calculated using the residency of unitholders in the Fund as at specific times, rather than the physical location of the Manager. A blended rate refund is filed with the Canada Revenue Agency on behalf of the Fund, in arrears, using each province's HST rate or GST rate in the case of non-participating provinces.

9. SOFT DOLLAR COMMISSIONS

Brokerage commissions paid to certain brokers may, in addition to paying for the cost of brokerage services in respect of security transactions, also provide for the cost of investment research services provided to the investment manager. The value of such research services included in commissions paid to brokers for the period ended June 30, 2022 and 2021 amounted to \$nil.



Head Office

610 Chartwell Rd, Suite 204
Oakville, Ontario L6J 4A5
Phone Number: 416.649.4541
Toll Free: 866.998.8298
Fax Number: 416.649.4542
Email: info@harvestportfolios.com

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in the Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.